Legend Biotech (LEGN) Depreciation & Amortization (CF) (2020 - 2026)

Legend Biotech (LEGN) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $2.4 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 4.35% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (down 52.21% YoY) and the FY2024 annual result came in at $23.4 million, up 14.22% from the prior year.
• Depreciation & Amortization (CF) grew to $2.4 million in Q1 2026, from $2.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $6.8 million in Q4 2024 to a low of $1.6 million in Q2 2022.
• A 5-year average of $3.0 million and a median of $2.6 million in 2022 frame the typical range for Depreciation & Amortization (CF).
• The widest YoY moves for Depreciation & Amortization (CF): up 12505.0% in 2022, down 38.93% in 2022.
• Tracing LEGN's Depreciation & Amortization (CF) over 5 years: stood at $2.5 million in 2022, then soared by 115.68% to $5.4 million in 2023, then rose by 27.0% to $6.8 million in 2024, then slumped by 68.42% to $2.1 million in 2025, then advanced by 11.84% to $2.4 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $2.4 million (Q1 2026), $2.1 million (Q3 2025), and $2.3 million (Q2 2025), per Business Quant data.